A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over at Least 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
Lay Description
Category
- Lungs, Breathing and Bronchial
- IRB Number
- 20220515HU
- NCT Number
- ct.gov registration not required
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- Eligible Genders
- Accepts Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Darcy Bair-Kelps
(210) 540-7100
bairkelps@uthscsa.edu
Hilda Pomroy
+1 (210) 450-9022
pomroy@uthscsa.edu
Hilda Pomroy
+1 (210) 450-9022
pomroy@uthscsa.edu
Principal Investigator
Anoop Nambiar